The Global Alliance For TB Drug Development Inc.
New York, NY
- UEI
- CA1RNRESAZU6
- CAGE
- 52VM4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 80 Pine St Fl 20, New York, NY 10005, USA
- Website
- tballiance.org
- Founded
- 2000
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| TB latitude (long-acting treatment innovation for tuberculosis drug effectiveness) - R220 - OPI section 7 - project… | National Institute of Allergy and Infectious Diseases | $802,418 | |
| Host-directed approaches to target granuloma pathways for treatment shortening in tuberculosis | Defense Health Agency | $7,352,643 | |
| Host-directed proteolysis-targeting chimera (protac) approach to target intracellular mycobacterium tuberculosis (MTB) | Defense Health Agency | $215,429 | |
| To develop a novel modulator targeting proteostasis for the treatment of m. Tuberculosis. | National Institute of Allergy and Infectious Diseases | $2,475,623 | |
| The TB alliance activity will support research studies to evaluate the safety and efficacy of novel TB drugs and… | Bureau for Global Health | $49,000,000 |
About The Global Alliance For TB Drug Development Inc.
The Global Alliance For TB Drug Development Inc., a tax-exempt nonprofit based in New York, develops novel therapeutics for tuberculosis and related infectious diseases as a federal grant and contract recipient, competing exclusively in full-and-open procurements with no set-aside status.
TB Alliance's federal footprint centers on research grants and development contracts from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Health Agency, and the U.S. Agency for International Development. NIAID is the primary funding source, accounting for four awards totaling $9.9 million in combined potential value — the largest being a $9.85 million definitive contract awarded May 10, 2024, running through April 30, 2028, to develop a novel modulator targeting proteostasis for the treatment of Mycobacterium tuberculosis under Executive Order 14398 (biodefense and antimicrobial-resistant infections). NIAID also funded a $802,418 Project Grant awarded May 7, 2026, for TB LATITUDE, a two-year initiative developing long-acting injectable formulation technologies for four TB drugs (TBAJ-876, TBAJ-587, telacebec, and pretomanid) designed to reduce active TB treatment duration to two months or less under CFDA 93.855 (Allergy and Infectious Diseases Research). The Defense Health Agency awarded a $7.35 million Project Grant on September 30, 2024, concluding September 29, 2028, supporting host-directed approaches targeting granuloma pathways and proteolysis-targeting chimera (PROTAC) methodology for shortened TB treatment, plus a $7.35 million Cooperative Agreement from the Bureau for Global Health (USAID) awarded September 30, 2021, concluding September 29, 2026, to evaluate safety and efficacy of novel TB drugs and treatment regimens in clinical development. TB Alliance acts as a sub-recipient on one grant awarded to the Regents of the University of California, San Francisco (July 10, 2024), providing TB drug development expertise and clinical guidance for a collaborative research effort.
Customer concentration is high but narrow: NIAID anchors 92% of the award count and 100% of combined potential value across the portfolio. Four awards (combined potential value $9.9 million) reach ultimate completion in the next twenty-four months, creating recompete exposure. Activity is sparse but recent — one award in 2015, one in 2019, one in 2021, then four in 2024 and one in 2026 — reflecting TB Alliance's transition into direct federal funding relationships. SCI-reported invoicing captures only $68 thousand in FY2024 across 0.2 FTEs on the NIAID contract, reflecting early-stage performance and the fact that SCI excludes research grants, goods, and the bulk of the vendor's federal revenue stream. Government-paid hourly rates on SCI-reportable service work run $154.91 per hour. TB Alliance self-performs its development work — no subcontractors were reported on the invoiced SCI contract, and the vendor operates primarily as a research-grant recipient rather than a services integrator or subcontractor to other primes.
Quick answers
What is The Global Alliance For TB Drug Development Inc.'s UEI?
The Global Alliance For TB Drug Development Inc.'s Unique Entity ID (UEI) in SAM.gov is CA1RNRESAZU6.
What is The Global Alliance For TB Drug Development Inc.'s CAGE code?
The Global Alliance For TB Drug Development Inc.'s CAGE code is 52VM4.
What is The Global Alliance For TB Drug Development Inc.'s primary NAICS code?
The Global Alliance For TB Drug Development Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is The Global Alliance For TB Drug Development Inc. located?
The Global Alliance For TB Drug Development Inc.'s physical address in SAM.gov is 80 Pine St Fl 20, New York, NY 10005, USA.
Is The Global Alliance For TB Drug Development Inc. registered in SAM.gov?
Yes. The Global Alliance For TB Drug Development Inc.'s SAM.gov registration is active through June 10, 2027.
What is The Global Alliance For TB Drug Development Inc.'s most recent federal award?
The Global Alliance For TB Drug Development Inc.'s most recent federal grant award is TB latitude (long-acting treatment innovation for tuberculosis drug effectiveness) - R220 - OPI section 7 - project… (R61AI197034), from National Institute of Allergy and Infectious Diseases, on May 7, 2026.
On GovTribe
See The Global Alliance For TB Drug Development Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors